Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles.
Rift Valley fever virus (RVFV) is an arthropod-borne pathogen that often results in severe morbidity and mortality in both humans and livestock. As its geographic range continues to expand, it presents a real threat to naïve populations around the world by accidental introduction (e.g., the result of increased travel) or intentional release (e.g., a bioterror event). While there is a clear need for a safe and efficacious vaccine against this emerging and re-emerging pathogen, no FDA-approved vaccine is currently available. This need was addressed by the establishment of novel mammalian and insect suspension cell line systems for the efficient production of RVF virus-like particle (VLP)-based vaccine candidates. A direct comparison of the production of RVF VLPs in these systems was performed. Optimization and characterization resulted in a production platform suitable for scale-up. Furthermore, RVF VLP-based vaccines were tested in a lethal challenge model and showed full protection, demonstrating that RVF VLPs present promising RVFV vaccine candidates.
Mandell
Robert B
RB
BioProtection Systems Corporation, Ames, IA 50010, USA.
Koukuntla
Ramesh
R
Mogler
Laura J K
LJ
Carzoli
Andrea K
AK
Holbrook
Michael R
MR
Martin
Brian K
BK
Vahanian
Nicholas
N
Link
Charles J
CJ
Flick
Ramon
R
D000818:Animals; D018929:Cell Culture Techniques / Q000379:methods; D002460:Cell Line; D004195:Disease Models, Animal; D006801:Humans; D051381:Rats; D011920:Rats, Inbred WF; D012295:Rift Valley Fever / Q000276:immunology / Q000517:prevention & control; D012296:Rift Valley fever virus / Q000235:genetics / Q000254:growth & development*; D018411:Spodoptera; D016019:Survival Analysis; D022721:Vaccines, Virosome / Q000096:biosynthesis / Q000235:genetics; D014765:Viral Vaccines / Q000096:biosynthesis* / Q000235:genetics
D022721:Vaccines, Virosome; D014765:Viral Vaccines